



Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.

A webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Poseida's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral Super piggyBac[®] DNA Delivery System, Cas-CLOVER[™] Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed global strategic collaborations with Roche and Takeda to unlock the promise of cell and gene therapies for patients. Learn more at www.poseida.com and connect with Poseida on [Twitter](#) and [LinkedIn](#).

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-hc-wainwright-cell-therapy-virtual-conference-301746302.html>

SOURCE Poseida Therapeutics, Inc.

Investor Contact - Alex Lobo, Managing Director, Stern Investor Relations, IR@poseida.com; Media Contact - Sarah Thailing, Senior Director, Corporate Communications and IR, Poseida Therapeutics, Inc., PR@poseida.com